Introduction
Alzheimer’s Disease (AD) is an irreversible degenerative disease of the central nervous system. According to statistics, there are currently about 10 million AD patients in China, and with the deepening of population aging, the number of AD patients in China is expected to approach 20 million by 2030. To promote the development of in vitro diagnostic technology for AD is an important part of the public health problem caused by the aging population in China. According to the latest NIA-AA guidelines, body fluid Aβ42/40, p-tau181, and p-tau217 are listed as the core markers for the diagnosis of AD. As the occurrence and development of AD is accompanied by neurodegeneration and neuroinflammation, neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) are also included in the guidelines as non-specific humoral markers for AD diagnosis. The publication of this guideline provides an authoritative basis for the hematological diagnosis of AD.
Product Feature
HKIG’s innovative products: AD blood marker series antigen proteins are expressed and prepared by mammalian cells, covering the full length of the protein, with high purity, maintaining the natural protein conformation to the greatest extent and close to the natural protein structure in the physiological state, which is helpful for the accurate quantitative detection of related indicators.
Product Information
| Name | Catalog No. | Size |
| beta Amyloid (1-42) antigen | 2029 | 50μg/100μg |
| beta Amyloid (1-40) antigen | 2030 | 50μg/100μg |
| neurofilament light antigen | 2031 | 50μg/100μg |
| tau (phosphorylation) antigen | 2035 | 50μg/100μg |
| tau (non-phospho) antigen | 2035N | 50μg/100μg |
| tau (phosphorylation) antigen isomer set | 2035I | 50μg/100μg |
| tau (non-phospho) antigen isomer set | 2035NI | 50μg/100μg |
| GFAP antigen | 2039 | 50μg/100μg |
Welcome for inquiry！
————————
Some of the pictures are from the Internet